Key Findings
- Purpose
To evaluate whether red blood cell (RBC)-bound ADP-ribosylation factor-like protein 13b (ARL13b), a cilia-associated protein, is associated with future vaso-occlusive crises (VOC) and disease severity in sickle cell disease (SCD), and to assess its potential as a prognostic biomarker. - Population (Model)
Retrospective pilot study involving 30 adults with SCD (24 HbSS, 1 HbSβ⁰-thalassemia, and 5 HbSC) and 27 age-matched healthy controls. Participants were followed for VOC-related hospitalizations occurring during the 3 months before and after enrollment. - Headline Result
The percentage of ARL13b-positive RBCs correlated with the number of pain crises occurring during the 3 months following enrollment (ρ = 0.4257, P = .0141), but not with pain crises during the preceding 3 months (ρ = 0.3158, P = .0951). ARL13b-positive RBCs also correlated with clinical severity score (ρ = 0.5997, P = .0005). No significant associations were observed between ARL13b and hemoglobin, bilirubin, lactate dehydrogenase (LDH), or hydroxyurea use. Soluble plasma ARL13b did not correlate with pain-crisis frequency. - Why It Matters
Reliable biomarkers capable of predicting VOC risk remain a major unmet need in SCD. This exploratory study suggests that RBC-bound ARL13b may reflect vascular injury processes associated with future pain crises and overall disease burden. If validated, ARL13b could potentially contribute to risk stratification and earlier identification of patients at increased risk for severe disease manifestations.
- Evidence Gaps & Limitations
This was a small retrospective pilot study involving only 30 patients. The proposed ARL13b threshold (>6.1% ARL13b-positive RBCs) was derived from this cohort and requires validation in larger, prospective, and more diverse populations. The study demonstrates associations rather than causation, and the predictive value of ARL13b for specific clinical outcomes remains to be confirmed.
Source: Journal of Sickle Cell Disease- “Ciliary protein ARL13b detected on RBCs as a potential indicative biomarker of vaso-occlusive crisis and disease severity in SCD: a retrospective pilot study”
Regulatory & Guideline Watch
Current SCD management guidelines do not recommend ARL13b testing for risk stratification or disease monitoring. Biomarker development remains an active area of investigation, particularly for identifying patients at higher risk of VOC and severe disease complications. This study provides preliminary evidence supporting further evaluation of RBC-bound ARL13b as a potential prognostic biomarker, but additional validation is needed before clinical implementation can be considered.